CLAIMS

1. A method for preparing dosage forms comprising low dose pharmaceutically active substances which comprises admixing carrier particles with a solution comprising the pharmaceutically active substance together with a binder therefor.

2. A method according to Claim 1 wherein the dose of pharmaceutically active substance is less than 100 μg.

3. A method according to Claim 2 wherein the dose of pharmaceutically active substance is less than 20 μg.

4. A method according to Claim 3 wherein the dose of pharmaceutically active substance is less than 1 μg.

5. A method according to Claims 1 – 4 wherein the ratio of solution comprising drug and binder: carrier is 5 – 50:100.

6. A method according to Claim 5 wherein the ratio of solution comprising drug and binder: carrier is 15 – 35:100.

7. A method according to Claim 6 wherein the ratio of solution comprising drug and binder: carrier is 20 – 30:100.

8. A method according to any preceding claim wherein the dosage form has a desired content uniformity of <7.5% RSD.

9. A method according to Claim 8 wherein the dosage form has a desired content uniformity of <6% RSD.

10. A method according to Claim 9 wherein the dosage form has a desired content uniformity of <3% RSD.

11. A method according to Claims 1 – 10 wherein the dosage form is a solid dosage form.

12. A method according to Claim 1 - 11 wherein the mixing step is carried out in a High Shear Mixer.

13. A method according to any preceding claim wherein the mixture is formulated into unit dosage presentations.

14. A pharmaceutical composition comprising a drug obtainable by the process of any preceding claim.

15. A method according to any claim 1-13 wherein the pharmaceutically active substance is Compound (1) (2-methyl-2-[4-{[(4-methyl–2-[4-trifluoromethylphenyl]-thiazol-5-ylcarbonyl)amino]methyl}phenoxy] propionic acid)



Compound (1)

or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

16. A pharmaceutical composition comprising 1-100 μg of Compound (1) or pharmaceutically acceptable salts, solvates and hydrolysable esters thereof together with a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising less than 20 μg of Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof together with a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising 1-18 μg of Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof together with a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising 1-10 μg of Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof together with a pharmaceutically acceptable carrier.

20. A pharmaceutical composition according to Claims 16–19 wherein Compound (1) or pharmaceutically acceptable salts, solvates or physiologically functiona derivatives thereof comprises form 2, form 6 and mixtures thereof.

21. A method of treatment of a human PPAR mediated disease or condition comprising administration to a subject a daily dose of 1-100 μg Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

22. A method according to Claim 21 wherein the daily dose of Compound (1)) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is less than 20μg.

23. A method according to Claim 22 wherein the daily dose of Compound (1)) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is 1-18μg.

24. A method according to Claim 23 wherein the daily dose of Compound (1)) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is 1-10μg.

25. A method according to Claim 21-24 where Compound (1) comprises form 2, form 6 or mixtures thereof.

26. Use of Compound (1) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof in a daily dose of 1-100 μg in the manufacture of a medicament for the treatment of a hPPAR mediated disease or condition

27. Use according to Claim 26wherein the daily dose of Compound (1)) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is less than 20μg.

28. Use according to Claim 27wherein the daily dose of Compound (1)) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is 1-18μg.

29. Use according to Claim 28 wherein the daily dose of Compound (1)) or pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof is 1-10μg.

30. Use according to Claim 26-29 where Compound (1) comprises form 2, form 6 or mixtures thereof.

31. Use or a method according to claims 21-30 wherein the Human (h) PPAR mediated diseases or conditions include dyslipidemia including associated diabetic dyslipidemia and mixed dyslipidemia, syndrome X (as defined in this application this embraces metabolic syndrome), heart failure, hypercholesteremia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, inflammation, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lung and gut and

regulation of appetite and food intake in subjects suffering from disorders such as obesity, anorexia bulimia, and anorexia nervosa, cancer, Alzheimers disease or other cognitive disorders.

5